

Corporate Profile

Luminex® Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. This industry depends on a broad range of tests, known as "bioassays," to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The in-house experts at Luminex have developed an innovative approach to bioassays, known as xMAP® technology. This groundbreaking technology enables companies and laboratories to perform bioassays more quickly and cost-effectively than with other systems, without sacrificing accuracy.

Luminex has been marketing the current generation of xMAP technology (formerly known as LabMAP®) worldwide since 1999. Thanks to its open-architecture platform, xMAP technology can be applied across a wide range of markets. In fact, xMAP technology-based systems are already in use by leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.

Escalating research and development spending, along with the evolution of pharmacogenomics, are fueling the growth of the drug discovery, clinical diagnostics and biomedical research markets - including both genomics and proteomics research. With this expansion of market opportunities, Luminex is strategically positioned for sustained growth and success.

Stock Performance

LMNX (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$19.19
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$17.64
Market Cap	\$845,724,908
Rolling EPS	0.33
PE Ratio	58.4865
Shares Outstanding	44,071,126

Data as of 08/16/17 4:00 p.m. ET

Recent Headlines

08/07/17 - 4:07 p.m.
Luminex Corporation Reports Second Quarter 2017 Financial Results

07/24/17 - 8:31 a.m.
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay

Primary IR Contact

Matthew Scalo
Senior Director, Investor Relations
Phone: 512.336.3587
E-mail: mscalo@luminexcorp.com



Upcoming Events

There are currently no events scheduled.

Corporate Governance

Nachum "Homi" Shamir	President and Chief Executive Officer
Harriss T. Currie	Senior Vice President, Finance, Chief Financial Officer and Treasurer
Nancy M. Fairchild, SPHR	Senior Vice President, Human Resources
Randall "Randy" Myers	Senior Vice President, Global Manufacturing and Quality
Richard Rew	Senior Vice President, General Counsel and Corporate Secretary
Tadd S. Lazarus, M.D.	Senior Vice President and Chief Medical Officer
Steven Back	Vice President, Manufacturing and Quality Surveillance
Todd C. Bennet	Senior Vice President, Global Sales and Customer Operations
David Bourne	Vice President, Business Development and Strategic Planning
Charles J. Collins, Ph.D.	Vice President, Systems Research and Development
Thomas J. Copa	Vice President, Technology and Strategic Partnerships
Ronald D. Dunn	Vice President, Global Regulatory and Clinical Affairs
Andrew D. Ewing	Vice President, Customer Experience
Scott C. Johnson, Ph.D.	Vice President, Product Development & Manufacturing
Kendel B. Martin, CPA	Vice President, Accounting
Eric S. Shapiro	Vice President, Global Marketing

SEC Filings

Filing Date	Form
08/08/17	10-Q
08/07/17	8-K
06/01/17	4
05/30/17	SD

Data provided by Nasdaq. Minimum 15 minutes delayed.